BioLife Solutions Reports Third Quarter 2024 Financial Results

Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54%GAAP net loss from continuing operations of$ 1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%Increasing Cell Processing revenue guidance by$ 2 million to $72.0 to$ 73.0 million; total 2024 revenue guidance of $98.0 million to$ 100.0 million reflecting impact of SciSafe divestitureConference call begins at 4:30 p.m. Eastern time todayBOTH ...